A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Natera, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 41,100 shares of NTRA stock, worth $6.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,100
Previous 60,700 32.29%
Holding current value
$6.92 Million
Previous $6.57 Million 20.54%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$97.75 - $129.67 $75.4 Million - $100 Million
-771,341 Reduced 25.31%
2,276,558 $289 Million
Q2 2024

Aug 14, 2024

BUY
$85.28 - $112.6 $60.2 Million - $79.5 Million
706,288 Added 30.16%
3,047,899 $330 Million
Q1 2024

May 15, 2024

BUY
$59.21 - $92.9 $40.2 Million - $63 Million
678,267 Added 40.78%
2,341,611 $214 Million
Q4 2023

Feb 14, 2024

BUY
$37.55 - $62.64 $62.3 Million - $104 Million
1,659,765 Added 46375.1%
1,663,344 $104 Million
Q3 2023

Nov 14, 2023

SELL
$43.4 - $62.52 $37.9 Million - $54.5 Million
-872,328 Reduced 99.59%
3,579 $158,000
Q2 2023

Aug 14, 2023

SELL
$47.08 - $55.16 $91.9 Million - $108 Million
-1,951,769 Reduced 69.02%
875,907 $42.6 Million
Q1 2023

May 15, 2023

SELL
$36.57 - $58.29 $8.09 Million - $12.9 Million
-221,272 Reduced 7.26%
2,827,676 $157 Million
Q4 2022

Feb 14, 2023

BUY
$34.17 - $47.91 $30.2 Million - $42.4 Million
884,865 Added 40.89%
3,048,948 $122 Million
Q3 2022

Nov 14, 2022

BUY
$36.93 - $56.68 $19.1 Million - $29.3 Million
517,051 Added 31.39%
2,164,083 $94.8 Million
Q2 2022

Aug 15, 2022

BUY
$28.13 - $44.54 $3.42 Million - $5.41 Million
121,511 Added 7.97%
1,647,032 $58.4 Million
Q1 2022

May 16, 2022

BUY
$30.32 - $91.33 $26.1 Million - $78.7 Million
862,070 Added 129.94%
1,525,521 $62.1 Million
Q4 2021

Feb 14, 2022

BUY
$86.26 - $119.0 $5.72 Million - $7.9 Million
66,347 Added 11.11%
663,451 $62 Million
Q3 2021

Nov 15, 2021

SELL
$100.17 - $126.36 $34.4 Million - $43.4 Million
-343,803 Reduced 36.54%
597,104 $66.5 Million
Q2 2021

Aug 16, 2021

BUY
$86.05 - $119.72 $24.7 Million - $34.4 Million
287,582 Added 44.02%
940,907 $107 Million
Q1 2021

May 17, 2021

BUY
$91.47 - $124.36 $24.7 Million - $33.5 Million
269,763 Added 70.33%
653,325 $66.3 Million
Q4 2020

Feb 16, 2021

BUY
$66.66 - $111.74 $9.29 Million - $15.6 Million
139,313 Added 57.04%
383,562 $38.2 Million
Q3 2020

Nov 16, 2020

BUY
$45.89 - $72.67 $10.6 Million - $16.8 Million
231,690 Added 1844.81%
244,249 $17.6 Million
Q2 2020

Aug 14, 2020

SELL
$26.36 - $49.86 $2.65 Million - $5.01 Million
-100,476 Reduced 88.89%
12,559 $626,000
Q1 2020

May 15, 2020

SELL
$17.27 - $40.17 $2.55 Million - $5.93 Million
-147,613 Reduced 56.63%
113,035 $3.38 Million
Q4 2019

Feb 14, 2020

BUY
$32.1 - $40.4 $5.82 Million - $7.32 Million
181,203 Added 228.09%
260,648 $8.78 Million
Q3 2019

Nov 14, 2019

SELL
$25.38 - $34.89 $1.59 Million - $2.19 Million
-62,738 Reduced 44.12%
79,445 $2.61 Million
Q1 2019

May 15, 2019

SELL
$11.34 - $20.62 $1.45 Million - $2.65 Million
-128,284 Reduced 47.43%
142,183 $0
Q4 2018

Feb 14, 2019

SELL
$12.32 - $24.38 $1.28 Million - $2.54 Million
-104,225 Reduced 27.82%
270,467 $3.78 Million
Q3 2018

Nov 13, 2018

BUY
$18.82 - $28.96 $4.42 Million - $6.8 Million
234,965 Added 168.16%
374,692 $0
Q2 2018

Aug 10, 2018

BUY
$8.79 - $19.98 $349,156 - $793,645
39,722 Added 39.72%
139,727 $0
Q1 2018

May 11, 2018

SELL
$9.0 - $11.95 $115,425 - $153,258
-12,825 Reduced 11.37%
100,005 $927,000
Q4 2017

Feb 09, 2018

BUY
$8.99 - $14.31 $100,679 - $160,257
11,199 Added 11.02%
112,830 $1.01 Million
Q3 2017

Nov 09, 2017

BUY
$8.02 - $13.33 $815,080 - $1.35 Million
101,631
101,631 $1.31 Million

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $16.3B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.